HK1137149A1 - Pharmaceutical composition for treatment of diabetic complications - Google Patents

Pharmaceutical composition for treatment of diabetic complications

Info

Publication number
HK1137149A1
HK1137149A1 HK10104542.3A HK10104542A HK1137149A1 HK 1137149 A1 HK1137149 A1 HK 1137149A1 HK 10104542 A HK10104542 A HK 10104542A HK 1137149 A1 HK1137149 A1 HK 1137149A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical composition
diabetic complications
diabetic
complications
Prior art date
Application number
HK10104542.3A
Other languages
English (en)
Inventor
Supreet K Deshpande
Sudhir A Kulkarni
Reena R Gollapudy
Original Assignee
Vlife Sciences Technologies Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlife Sciences Technologies Pvt Ltd filed Critical Vlife Sciences Technologies Pvt Ltd
Publication of HK1137149A1 publication Critical patent/HK1137149A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10104542.3A 2007-01-29 2010-05-10 Pharmaceutical composition for treatment of diabetic complications HK1137149A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1960MU2006 2007-01-29
PCT/IN2008/000044 WO2008093356A1 (en) 2007-01-29 2008-01-24 Pharmaceutical composition for treatment of diabetic complications

Publications (1)

Publication Number Publication Date
HK1137149A1 true HK1137149A1 (en) 2010-07-23

Family

ID=47263792

Family Applications (2)

Application Number Title Priority Date Filing Date
HK10104542.3A HK1137149A1 (en) 2007-01-29 2010-05-10 Pharmaceutical composition for treatment of diabetic complications
HK15105526.5A HK1204932A1 (en) 2007-01-29 2015-06-10 Pharmaceutical composition for treatment of diabetic complications

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15105526.5A HK1204932A1 (en) 2007-01-29 2015-06-10 Pharmaceutical composition for treatment of diabetic complications

Country Status (11)

Country Link
US (1) US8686051B2 (ja)
EP (2) EP2444077A1 (ja)
JP (1) JP5240586B2 (ja)
CN (2) CN104189906A (ja)
CA (1) CA2680843C (ja)
CY (1) CY1113784T1 (ja)
DK (1) DK2114386T3 (ja)
ES (1) ES2400004T3 (ja)
HK (2) HK1137149A1 (ja)
WO (1) WO2008093356A1 (ja)
ZA (1) ZA200905970B (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2480204E (pt) * 2009-09-22 2014-01-22 Vlife Sciences Technologies Pvt Ltd Formulação tópica para úlceras do pé diabético
WO2013109949A1 (en) * 2012-01-19 2013-07-25 Ibt Usa Inc. Therapeutic uses of tetrachlorodecaoxygen (tcdo)
US20150111833A1 (en) * 2012-04-20 2015-04-23 Howard University Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease
US10159688B2 (en) * 2013-03-15 2018-12-25 M. Alphabet 3, L.L.C. Methods and compositions for enhancing oxygen levels in tissues
WO2015031110A2 (en) * 2013-08-27 2015-03-05 The Regents Of The University Of California Combination therapy to promote wound healing
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CN104971211A (zh) * 2014-04-02 2015-10-14 王嘉影 一种用于治疗糖尿病神经源性膀胱病的复方中药汤剂
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
CN105770860B (zh) * 2016-03-16 2021-01-05 哈尔滨医科大学 生长分化因子-11在促进糖尿病伤口愈合中的用途
MX2019012476A (es) * 2017-04-21 2020-02-12 Hoffman Steven Composiciones y metodos para tratar la retinopatia.
EP3731836B1 (en) * 2017-12-27 2023-09-20 Genepred Biotechnologies Beta-blockers for treating and/or preventing pathological scars
US11400070B2 (en) * 2018-05-03 2022-08-02 Alimera Sciences, Inc. Methods of treating retinal diseases
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11154518B2 (en) * 2018-12-28 2021-10-26 Chang Gung Memorial Hospital, Linkou Methods and apparatus for treating a wound
CN116056693A (zh) * 2020-07-10 2023-05-02 长庚医疗财团法人林口长庚纪念医院 β-1肾上腺素受体拮抗剂用于制备减少表皮生长因子受体抑制剂诱导的上皮细胞损伤以及抑制癌细胞的组合物的用途
CN114053419B (zh) * 2021-12-09 2023-02-24 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) 去甲肾上腺素或β-肾上腺素能受体抑制剂在制备治疗糖尿病神经修复的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL300886A (ja) * 1962-11-23
US3655663A (en) * 1969-04-21 1972-04-11 Burton K Wasson 4-(3-secondary amino-2-hydroxy-proxy) 1 2 5-thiadiazoles
US4593119A (en) * 1980-11-28 1986-06-03 American Hospital Supply Corporation Method for treatment or prophylaxis of cardiac disorders
JPS58206519A (ja) 1982-05-27 1983-12-01 Kowa Co 外用β−遮断剤
US4897417A (en) 1988-12-15 1990-01-30 E. I. Du Pont De Nemours & Co. Prodrugs of 3,4-hydroxy benzoyloxypropanolamines
DE69212646T2 (de) 1991-03-18 1997-03-13 Sepracor Inc Zubereitung und verfahren enthaltend optisch reines s-metoprolol
AP2001002206A0 (en) 1998-12-11 2001-09-30 Bakulesh Mafatlal Khamar The process for manufacturing formulation of topical beta blockers with improved efficacy.
WO2003059372A2 (en) 2001-12-29 2003-07-24 Novo Nordisk A/S Combined use of a glp-1 compound and a modulator of diabetic late complications
WO2006108176A2 (en) 2005-04-08 2006-10-12 The Regents Of The University Of California Wound healing composition

Also Published As

Publication number Publication date
WO2008093356A1 (en) 2008-08-07
ES2400004T3 (es) 2013-04-04
EP2114386B1 (en) 2012-12-26
EP2114386A1 (en) 2009-11-11
CN101616662B (zh) 2015-07-29
CY1113784T1 (el) 2016-07-27
DK2114386T3 (da) 2013-03-18
JP2011509917A (ja) 2011-03-31
US8686051B2 (en) 2014-04-01
ZA200905970B (en) 2012-08-29
CA2680843C (en) 2016-05-31
EP2444077A1 (en) 2012-04-25
US20110021526A1 (en) 2011-01-27
CN101616662A (zh) 2009-12-30
JP5240586B2 (ja) 2013-07-17
CN104189906A (zh) 2014-12-10
EP2114386B9 (en) 2013-09-18
CA2680843A1 (en) 2008-08-07
HK1204932A1 (en) 2015-12-11

Similar Documents

Publication Publication Date Title
HK1204932A1 (en) Pharmaceutical composition for treatment of diabetic complications
LT2303330T (lt) Farmacinės kompozicijos, skirtos parkinsono ligai gydyti
ZA200902374B (en) Compositions useful for the treatment of diabetes
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
EP3189859B8 (en) Composition for treatment of cartilage disease
IL200090A0 (en) Composition for treatment of undifferentiated-type of gastric cancer
IL199907A0 (en) Composition for treatment of pancreatic cancer
EP2322221A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
GB0909297D0 (en) Composition for the treatment of skin conditions
EP2172207A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES AND METHOD FOR THE PRODUCTION THEREOF
GB2469220B (en) Pharmaceutical composition for treating diabetes and preparation method thereof
EP2210621A4 (en) COMPOSITION FOR THE TREATMENT OF JOINT DISEASES
EP2301543A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia
PL385972A1 (pl) Kompozycja farmaceutyczna do leczenia chorób przyzębia
EP2305300A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
EP2402342A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
HK1145399A1 (en) Pharmaceutical composition for treating hemorrhoids
EP2382992A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADIPOSITAS OR DIABETES
EP2331099A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES MELLITUS